These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 26717884)

  • 21. Cost-effectiveness of statins for primary cardiovascular prevention in chronic kidney disease.
    Erickson KF; Japa S; Owens DK; Chertow GM; Garber AM; Goldhaber-Fiebert JD
    J Am Coll Cardiol; 2013 Mar; 61(12):1250-8. PubMed ID: 23500327
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types.
    Armstrong EP
    J Manag Care Pharm; 2010 Apr; 16(3):217-30. PubMed ID: 20331326
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A multi-country health economic evaluation of highly concentrated N-3 polyunsaturated fatty acids in secondary prevention after myocardial infarction.
    Lamotte M; Annemans L; Kawalec P; Zoellner Y
    Pharmacoeconomics; 2006; 24(8):783-95. PubMed ID: 16898848
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-Effectiveness Analysis of Corneal Collagen Crosslinking for Progressive Keratoconus.
    Godefrooij DA; Mangen MJ; Chan E; O'Brart DPS; Imhof SM; de Wit GA; Wisse RPL
    Ophthalmology; 2017 Oct; 124(10):1485-1495. PubMed ID: 28532974
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Projected cost-effectiveness of ezetimibe/simvastatin compared with doubling the statin dose in the United Kingdom: findings from the INFORCE study.
    Reckless J; Davies G; Tunceli K; Hu XH; Brudi P
    Value Health; 2010; 13(6):726-34. PubMed ID: 20561328
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A multi-country health-economic evaluation of highly concentrated n-3 polyunsaturated fatty acids in the secondary prevention after myocardial infarction.
    Lamotte M; Annemans L; Kawalec P; Zoellners Y
    Herz; 2006 Dec; 31 Suppl 3():74-82. PubMed ID: 17575809
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness of high-dose atorvastatin compared with regular dose simvastatin.
    Lindgren P; Graff J; Olsson AG; Pedersen TJ; Jönsson B;
    Eur Heart J; 2007 Jun; 28(12):1448-53. PubMed ID: 17371782
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Costs and consequences of clopidogrel versus aspirin for secondary prevention of ischaemic events in (high-risk) atherosclerotic patients in Sweden: a lifetime model based on the CAPRIE trial and high-risk CAPRIE subpopulations.
    Logman JF; Heeg BM; Herlitz J; van Hout BA
    Appl Health Econ Health Policy; 2010; 8(4):251-65. PubMed ID: 20578780
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness of clopidogrel in myocardial infarction with ST-segment elevation: a European model based on the CLARITY and COMMIT trials.
    Berg J; Lindgren P; Spiesser J; Parry D; Jönsson B
    Clin Ther; 2007 Jun; 29(6):1184-202. PubMed ID: 17692733
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Results of a Markov model analysis to assess the cost-effectiveness of a single tablet of fixed-dose amlodipine and atorvastatin for the primary prevention of cardiovascular disease in Korea.
    Liew D; Park HJ; Ko SK
    Clin Ther; 2009 Oct; 31(10):2189-203; discussion 2150-1. PubMed ID: 19922890
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness of a population-based AAA screening program for men over 65 years old in Iran.
    Daroudi R; Shafe O; Moosavi J; Salimi J; Bayazidi Y; Zafarghandi MR; Maleki M; Moini M; Farshidmehr P; Sadeghipour P
    Cost Eff Resour Alloc; 2021 May; 19(1):29. PubMed ID: 33985531
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluating the cost-effectiveness of universal hepatitis B virus vaccination in Iran: a Markov model analysis.
    Mokhtari AM; Barouni M; Moghadami M; Hassanzadeh J; Dewey RS; Mirahmadizadeh A
    Hum Vaccin Immunother; 2021 Jun; 17(6):1825-1833. PubMed ID: 33734949
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness of adding rh-endostatin to first-line chemotherapy in patients with advanced non-small-cell lung cancer in China.
    Wu B; Chen H; Shen J; Ye M
    Clin Ther; 2011 Oct; 33(10):1446-55. PubMed ID: 21992806
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prescribing high-dose lipid-lowering therapy early to avoid subsequent cardiovascular events: is this a cost-effective strategy?
    Ara R; Pandor A; Stevens J; Rafia R; Ward SE; Rees A; Durrington PN; Reynolds TM; Wierzbicki AS; Stevenson M
    Eur J Prev Cardiol; 2012 Jun; 19(3):474-83. PubMed ID: 21460076
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost effectiveness of prostacyclins in pulmonary arterial hypertension.
    Roman A; Barberà JA; Escribano P; Sala ML; Febrer L; Oyagüez I; Sabater E; Casado MA
    Appl Health Econ Health Policy; 2012 May; 10(3):175-88. PubMed ID: 22452448
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20,536 people.
    ; Mihaylova B; Briggs A; Armitage J; Parish S; Gray A; Collins R
    BMJ; 2006 Dec; 333(7579):1145. PubMed ID: 17098764
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Economic evaluation of clopidogrel in acute coronary syndrome patients without ST-segment elevation in Greece: a cost-utility analysis.
    Kourlaba G; Fragoulakis V; Maniadakis N
    Appl Health Econ Health Policy; 2012 Jul; 10(4):261-71. PubMed ID: 22667992
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term cost-effectiveness of providing full coverage for preventive medications after myocardial infarction.
    Ito K; Avorn J; Shrank WH; Toscano M; Spettel C; Brennan T; Choudhry NK
    Circ Cardiovasc Qual Outcomes; 2015 May; 8(3):252-9. PubMed ID: 25944633
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Economic evaluation of ezetimibe treatment in combination with statin therapy in the United States.
    Davies GM; Vyas A; Baxter CA
    J Med Econ; 2017 Jul; 20(7):723-731. PubMed ID: 28426345
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness of apixaban compared to warfarin in the management of atrial fibrillation in Australia.
    Ademi Z; Pasupathi K; Liew D
    Eur J Prev Cardiol; 2015 Mar; 22(3):344-53. PubMed ID: 24281250
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.